Arexvy (respiratory syncytial virus vaccine, adjuvanted) is a brand-name intramuscular injection that’s prescribed to help prevent a lung infection that’s caused by RSV infection in adults.

Arexvy is a vaccine used to prevent certain infections caused by the respiratory syncytial virus (RSV). Learn about cost, how to find savings, and more.

U.K.-based biopharmaceutical company GSK plc (GSK) said on Friday that the European Medicines Agency (EMA) has accepted its ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

GSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted the company's regulatory ...

AREXVY is not approved for use in persons <50 years of age Vaccination with AREXVY may not result in protection of all vaccine recipients Please see full Prescribing Information for AREXVY.

Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult ...

Cumulatively, the efficacy of a single Arexvy dose to prevent RSV-related lower respiratory tract disease over three RSV seasons was 62.9%. Efficacy over three seasons was 51.1%.

AREXVY is not approved for use in persons <50 years of age Vaccination with AREXVY may not result in protection of all vaccine recipients Please see full Prescribing Information for AREXVY.